Application of berberine derivative NBD-125 in preparation of medicine for preventing and / or treating obesity

By using the berberine derivative NBD-125, the problem of unsatisfactory efficacy and safety in the treatment of obesity has been solved, and significant effects have been achieved in inhibiting weight gain, enhancing metabolism and thermogenesis, inhibiting the formation of white adipose tissue, and enhancing the function of brown adipose tissue.

CN119033779APending Publication Date: 2024-11-29厦门丹凝中医药研究院有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411170945.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

In the existing technology, the efficacy and safety of drugs for treating obesity are not ideal. Berberine has low solubility and bioavailability, which limits its application in the treatment of obesity.

Method used

The berberine derivative NBD-125 is used to prevent and treat obesity by inhibiting weight gain, enhancing metabolism and thermogenesis, inhibiting the formation of white adipose tissue and enhancing the function of brown adipocytes, and blocking the differentiation of preadipocytes.

Benefits of technology

It significantly inhibits high-fat diet-induced weight gain, enhances metabolism and thermogenesis, inhibits white adipose tissue formation, enhances brown adipocyte function, and blocks preadipocyte differentiation, with effects superior to berberine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033779A_ABST
    Figure CN119033779A_ABST
Patent Text Reader

Abstract

The invention relates to application of a berberine derivative NBD-125 in preparation of a medicine for preventing and / or treating obesity, and belongs to the technical field of obesity treatment. The invention provides an application of a berberine derivative NBD-125 in preparation of a medicine for preventing and / or treating obesity. The berberine derivative NBD-125 can prevent and / or treat obesity, and the effect of the berberine derivative NBD-125 is obviously superior to that of berberine; the berberine derivative NBD-125 can inhibit weight gain, enhance metabolism and / or heat production, inhibit white fat generation, inhibit white fat reduction and / or inhibit white fat cell enlargement, and inhibit preadipocytes from differentiating to adipocytes and / or lipid accumulation, and all inhibition indexes are superior to berberine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of obesity treatment, and specifically relates to the use of a berberine derivative NBD-125 in the preparation of a drug for preventing and / or treating obesity. Background Art

[0003] Obesity refers to an imbalance in energy homeostasis, excessive accumulation and / or abnormal distribution of body fat, and weight gain caused by excessive food intake or changes in body metabolism. It is a chronic metabolic disease caused by the interaction of multiple factors. Studies have found that obese people are more likely to suffer from high blood lipids, high blood pressure and other diseases. [1-3] In addition to lifestyle changes, diet control, exercise, medication and surgery, a variety of drugs have been tried in the clinic to treat obesity (such as thyroid extract, 2-nitrophenol and amphetamine), but the efficacy and safety are not ideal. Developing new drugs to treat obesity and exploring effective intervention methods for obesity are issues that need to be addressed urgently.

[0004] Berberine (BBR) is the active ingredient of traditional Chinese medicines such as Coptis chinensis and Phellodendron chinense, and has been used to treat dysentery and enteritis. In recent years, studies have found that berberine can also fight tumors, lower blood sugar and blood lipids, and has potential weight loss effects. [4-6] However, due to the extremely low solubility and bioavailability of berberine, the clinical application of berberine is greatly limited. The present invention has developed a berberine derivative NBD-125 with significantly improved solubility and bioavailability and retains the safety and low toxicity of berberine. [7] However, the prior art does not report the application of berberine derivative NBD-125 in the treatment of obesity.

[0005] [1]ROSEN ED, SPIEGELMAN B M.What we talk about when we talk about fat[J]. Cell, 2014, 156(1-2): 20-44.

[0006] [2]YANOVSKI JA. Obesity: Trends in underweight and obesity-scale oftheproblem[J]. Nat Rev Endocrinol, 2018, 14(1): 5-6.

[0007] [3] BLUHER M. Obesity:global epidemiology and pathogenesis[J]. Nature Reviews Endocrinology,2019,15(5):288-98.

[0008] [4] Leng SH, Lu FR, Xu LJ. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharm. Sin. 2004, 25:496-502.

[0009] [5] Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-64.

[0010] [6] Yin J, Gao ZG, Liu D, Liu ZJ, Ye JP. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 2008, 294:E148-56.

[0011] [7] Xu B, Jiang X, Xiong J, Lan J, Zhong L, Wang X, Cao H, Zhan Y, Zhang Y, Hu T. Structure-Activity Relationship Study Enables the Discovery of a Novel Berberine Analogue as RXRα Activator to Inhibit Colon Cancer. J. Med. Chem. 2020, 63:5841-5855. Summary of the Invention

[0012] The object of the present invention is to provide the use of berberine derivative NBD-125 in the preparation of a drug for preventing and / or treating obesity. Berberine derivative NBD-125 can achieve the prevention and / or treatment of obesity.

[0013] The present invention provides the use of a berberine derivative NBD-125 in preparing a drug for preventing and / or treating obesity.

[0014] Preferably, the obesity includes obesity induced by a high-fat diet.

[0015] The present invention also provides the use of the berberine derivative NBD-125 in preparing a medicine for inhibiting weight gain.

[0016] The present invention also provides the use of the berberine derivative NBD-125 in the preparation of drugs for enhancing metabolism and / or heat production.

[0017] The present invention also provides the use of the berberine derivative NBD-125 in preparing a drug for inhibiting the formation of white fat.

[0018] Preferably, the inhibiting of white fat production includes inhibiting the increase of white fat and / or inhibiting the enlargement of white fat cells.

[0019] The present invention also provides the use of the berberine derivative NBD-125 in preparing a medicine for enhancing the function of brown fat cells.

[0020] The present invention also provides the use of the berberine derivative NBD-125 in the preparation of a drug for inhibiting the differentiation of pre-adipocytes into adipocytes and / or lipid accumulation.

[0021] Preferably, the inhibiting the differentiation of preadipocytes into adipocytes comprises inhibiting the early mitotic clones of preadipocyte differentiation.

[0022] Preferably, the structure of the berberine derivative NBD-125 is as shown in Formula I:

[0023]

[0024] The present invention provides the use of a berberine derivative NBD-125 in the preparation of a drug for preventing and / or treating obesity. The berberine derivative NBD-125 can prevent and / or treat obesity, and the effect is significantly better than berberine; and the berberine derivative NBD-125 can inhibit weight gain, enhance metabolism and / or heat production, inhibit white fat production, inhibit white fat reduction and / or inhibit the enlargement of white fat cells, and inhibit the differentiation of pre-adipocytes into adipocytes and / or lipid accumulation, and each inhibition index is better than berberine. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following is a brief introduction to the drawings required for use in the embodiments. In the drawings, descriptions and embodiments, NBD-125 is abbreviated as B125, and berberine is represented by its English abbreviation BBR. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0026] Figure 1 The weight loss effect of B125 provided by the present invention in C57BL / 6 mice induced by a high-fat diet; wherein a. a high-fat diet during B125 administration (HighFat =(a) Changes in body weight of mice in the a. diet (HFD) group; b) Changes in the total amount of white adipose tissue of mice in each group; c) Changes in the weight of subcutaneous adipose tissue of mice in each group; d) Changes in the weight of visceral adipose tissue of mice in each group; e) Changes in the weight of brown adipose tissue of mice in each group; f) Representative images of hematoxylin-eosin (HE) staining of white fat and brown fat of mice in each group; g) Statistical graph of the proportion of white fat cells of different sizes in mice in the HFD group; h) Statistical graph of the proportion of brown fat cells of different sizes in mice in the HFD group; n=6, *Compared with HFD-Saline, *P<0.05, **P<0.01, ***P<0.005, ****P<0.001; #Compared with HFD-BBR, #P<0.05, ##P<0.01, ###P<0.005, ####P<0.001;

[0027] Figure 2 The results of the B125 provided by the present invention enhancing the metabolism and heat production of HFD-induced obese C57BL / 6 mice; wherein a. 2 Statistical graph of consumption and light cycle (7-19 o'clock) and dark cycle (19-7 o'clock); b. CO of HFD mice 2 c. Statistical graph of heat production and light cycle and dark cycle of HFD mice; d. Statistical graph of respiratory exchange ratio (RER) and light cycle and dark cycle of HFD mice; (n=6, * compared with HFD-Saline, *P<0.05; # compared with HFD-B125 and HFD-BBR, #P<0.05);

[0028] Figure 3The results of the B125 provided by the present invention inhibiting the mitosis and cloning of pre-adipocytes; wherein, a. a cell cycle distribution diagram of the early mitosis and cloning stage of pre-adipocyte differentiation after B125 treatment for different time periods detected by flow cytometry; un: 0 point of induction of differentiation and drug treatment; 16h-Vehicle: induced differentiation 16h + B125 solvent DMSO treatment group; 16h-B-5μM: induced differentiation 16h + 5μM BBR treatment 16h group; 16h-B-10μM: induced differentiation 16h + 10μM BBR treatment 16h group; 16h-B125-5μM: induced differentiation 16h + 5μM B125 treatment 16h group; 16h-B125-10μM: induced differentiation 16h + 10μM B125 treatment group for 16h; 28h-Vehicle: induced differentiation for 28h + B125 solvent DMSO treatment group; 28h-B-5μm: induced differentiation for 28h + 5μM BBR treatment for 26h; 28h-B-10μM: induced differentiation for 28h + 10μM BBR treatment for 28h; 28h-B125-5μM: induced differentiation for 28h + 5μM B125 treatment for 28h; 28h-B125-10μM: induced differentiation for 28h + 10μM B125 treatment for 28h; b. Period distribution statistics; left side: 16h; right side: 28h;

[0029] Figure 4 The results of B125 provided by the present invention inhibiting the differentiation of pre-adipocytes and intracellular lipid accumulation are shown in Figure 1; wherein, a. representative images of Oil Red O staining (bottom) and phase contrast (top); b. lipid accumulation content of 3T3-L1 adipocytes; n=3, * compared with HFD-Vehicle, *P<0.05, **P<0.01, ***P<0.005, ****P<0.001; # compared with HFD-B125 and HFD-BBR, #P<0.05. DETAILED DESCRIPTION

[0030] The present invention provides the use of a berberine derivative NBD-125 (also known as a berberine derivative NBD-125, abbreviated as B125) in the preparation of a drug for preventing and / or treating obesity. In the present invention, the obesity preferably includes obesity induced by a high-fat diet. The present invention does not specifically limit the source of the berberine derivative NBD-125, and it can be prepared by conventional methods, such as the patent with application number "201910484491.4" and invention name "A berberine derivative NBD-125 and its application". In the present invention, the structure of the berberine derivative NBD-125 is shown in Formula I:

[0031]

[0032] The present invention also provides the use of a berberine derivative NBD-125 in the preparation of a drug for inhibiting weight gain. In the present invention, the weight gain is preferably weight gain induced by a high-fat diet. The test results show that the berberine derivative NBD-125 can significantly inhibit the weight gain of C57BL / 6 obese mice induced by a high-fat diet, and has no significant effect on their food intake.

[0033] The present invention also provides the use of a berberine derivative NBD-125 in the preparation of a drug for enhancing metabolism and / or heat production. In the present invention, the enhanced metabolism and / or heat production is preferably enhanced metabolism and / or heat production induced by a high-fat diet. The test results show that the berberine derivative NBD-125 can significantly increase the oxygen consumption, carbon dioxide production and heat production of mice on a high-fat diet, but does not change the respiratory exchange rate, indicating that B125 can significantly enhance the metabolism and heat production of obese mice induced by a high-fat diet, thereby inhibiting weight gain.

[0034] The present invention also provides the use of the berberine derivative NBD-125 in preparing a drug for inhibiting the formation of white fat.

[0035] In the present invention, the inhibition of white fat production includes inhibiting the increase of white fat and / or inhibiting the enlargement of white fat cells. NBD-125 can significantly inhibit the increase of white fat in C57BL / 6 obese mice induced by a high-fat diet; NBD-125 can also significantly inhibit the enlargement of white fat cells, exerting the effect of inhibiting white fat production.

[0036] The present invention also provides the use of a berberine derivative NBD-125 in the preparation of a drug for enhancing the function of brown fat cells. In the present invention, the enhancement of the function of brown fat cells preferably includes enhancing the metabolism and heat production of brown adipose tissue. In the present invention, the enhancement of the function of fatty acid cells preferably includes increasing the number of small brown fat cells while the weight of brown adipose tissue remains unchanged. The function of brown fat cells is mainly heat production. The greater the relative proportion of brown adipose tissue, the higher the metabolism and the less likely it is to be obese. The weight of brown adipose tissue remains unchanged, but the cell volume is small (less fat), and it is inferred that the weight loss function and potential are strong. The experimental results show that under the action of NBD-125, the weight of brown fat remains unchanged, but the area of ​​brown adipose tissue is 200 to 500 μm 2 The number of cells was significantly reduced, 10-50 μm 2 The number of cells increased significantly, indicating that the function of brown fat cells was enhanced and their potential was greater.

[0037] The present invention also provides the use of a berberine derivative NBD-125 in the preparation of a drug for inhibiting the differentiation of pre-adipocytes into adipocytes and / or lipid accumulation. In the present invention, the inhibition of the differentiation of pre-adipocytes into adipocytes includes inhibiting the early mitotic clones of pre-adipocyte differentiation. The test results show that NBD-125 can significantly block the early mitotic clones of 3T3-L1 differentiation, thereby inhibiting the entire process of fat differentiation; NBD-125 can also significantly inhibit the lipid accumulation of 3T3-L1 pre-adipocyte differentiation.

[0038] To further illustrate the present invention, the application of the berberine derivative NBD-125 provided by the present invention in the preparation of a drug for preventing and / or treating obesity is described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.

[0039] Example 1

[0040] 1. In vivo animal model

[0041] Four-week-old male C57BL / 6J mice (SPF grade) were purchased from the Experimental Animal Center of Xiamen University and lived in a room maintained at a temperature of (24-26°C) and humidity controlled, with free access to food and sterile water; they were used for experiments after acclimating to the environment for 2 weeks. For the study of specific diets, 6-week-old C57BL / 6J mice were randomly divided into a normal diet group and a high-fat diet group. The normal diet group (NFD) still maintained a standard diet, and the high fat diet group (HFD) was given a high fat diet (60% fat, Trophic Animal Feed High-Tech Co., Ltd, China; Catalog No. TP23400) for 8 weeks. The HFD group was then randomly divided into three groups and intraperitoneally injected with normal saline (0.9% Saline), 10 μM / kg BBR (positive control), and 10 μM / kg B125 every other day for 60 days. The injection volumes of the three groups were equal, and the molar / body weight concentrations of BBR and B125 were equal.

[0042] 1. Effect of B125 on the body weight of C57BL / 6 obese mice induced by high-fat diet

[0043] During the above experiment, the body weight and food intake of mice were tested regularly (4 days / time). On day 0, the average body weight of mice in the HFD group was similar (HFD-Saline group: 32.13g; HFD-BBR group: 31.87g; HFD-B125 group: 32.01g). Compared with the HFD-Saline group, the average body weight of mice in the HFD-B125 group was significantly reduced, with significant differences of p < 0.05 on day 8 and p < 0.001 on day 20. Compared with the HFD-BBR group, the average body weight of mice in the HFD-B125 group gradually decreased, with significant differences of p < 0.05 on day 28 and p < 0.001 on day 52. ​​At the same time, the average body weight of mice in the HFD-BBR group was significantly lower than that in the HFD-Saline group on day 20 (p < 0.05) and p < 0.001 on day 56. Therefore, B125 treatment can significantly inhibit the weight gain of C57BL / 6 obese mice induced by a high-fat diet ( Figure 1 The effect was significantly better than that of BBR. The changes in the food intake of each group of mice during the experiment were observed and statistically analyzed, and it was found that the drug had no significant effect on food intake.

[0044] 2. Effects of B125 on metabolism and thermogenesis in C57BL / 6 obese mice induced by a high-fat diet

[0045] After 30 intraperitoneal injections (60 days), mice in different treatment groups of high-fat diet (HFD-Saline, HFD-BBR, HFD-B125) were placed in a Sable Promethion calorimetric system (metabolic cage), 1 mouse / cage. The instrument automatically recorded the oxygen consumption, carbon dioxide release, heat production, respiratory exchange rate, food intake, and X-axis, Y-axis, and Z-axis displacements of the mice in the metabolic cage (representing their exercise capacity) every five minutes for more than 3 days (72 hours). The middle 24-hour data were selected for statistical analysis, and 7:00-19:00 was marked as the light cycle (Light Cycle), and 19:00-7:00 was marked as the dark cycle (Dark Cycle). The data were divided by the weight of the mice to calculate the oxygen consumption, carbon dioxide production, heat production, respiratory exchange rate and other indicators of each mouse in each group (n=5), and the average values ​​were taken for plotting (for details of some indicators, see Figure 2 ) and compared between groups. The results showed that B125 could not change the food intake of mice, but could significantly increase the oxygen consumption of mice fed a high-fat diet ( Figure 2 a) Carbon dioxide production ( Figure 2 b) and heat production ( Figure 2 c), but did not change the respiratory exchange rate ( Figure 2 Specifically, Figure 2From the oxygen consumption curve on the left in a, it can be seen that the average oxygen consumption (ml / kg / h) of mice in the HFD-B125 group was significantly higher than that in the HFD-Saline and HFD-BBR groups. The light cycle and dark cycle statistics on the right showed that during the light cycle, the average oxygen consumption of the three groups of mice was 2028.33ml / kg / h, 2539.70ml / kg / h and 3022.68ml / kg / h, respectively. The statistical results showed that HFD-B125 vs HFD-Saline: p < 0.001, HFD-BBR vs HFD-Saline: p < 0.01, HFD-B125 vs HFD-BBR: p < 0.01; during the dark cycle, the average oxygen consumption of the three groups of mice was 2158.30ml / kg / h, 2663.98ml / kg / h and 3014.18ml / kg / h, respectively. The statistical results showed that HFD-B125 vs HFD-Saline: p < 0.001, HFD-BBR vs HFD-Saline: p < 0.01, HFD-B125 vs HFD-BBR: p < 0.05. Therefore, regardless of the light cycle or dark cycle, the effect of B125 is significantly better than that of BBR. Figure 2 From the carbon dioxide release curve on the left in b, it can be seen that the average carbon dioxide release (ml / kg / h) of mice in the HFD-B125 group was significantly higher than that in the HFD-Saline and HFD-BBR groups. The light cycle and dark cycle statistical graphs on the right showed that during the light cycle, the carbon dioxide consumption of the three groups of mice was 1569.16ml / kg / h, 2017.23ml / kg / h and 2260.81ml / kg / h, respectively. The statistical results showed that HFD-B125 vs HFD-Saline: p < 0.001, HFD-BBR vs HFD-Saline: p < 0.01, HFD-B125 vs HFD-BBR: p < 0.05; during the dark cycle, the carbon dioxide consumption of the three groups of mice was 1645.49ml / kg / h, 2140.42ml / kg / h and 2281.00ml / kg / h, respectively. The statistical results showed that HFD-B125 vs HFD-Saline: p < 0.001, HFD-BBR vs HFD-Saline: p < 0.01, therefore, the effect of B125 is significantly better than that of BBR in both light and dark cycles. Figure 2From the total heat curve on the left in c, it can be seen that the heat production (Kcal / kg / h) of the mice in the HFD-B125 group was significantly higher than that in the HFD-Saline and HFD-BBR groups. The light cycle and dark cycle statistical graphs on the right showed that during the light cycle, the heat production of the three groups of mice was 583.32ml / kg / h, 731.09ml / kg / h and 854.28ml / kg / h, respectively. The statistical results showed that HFD-B125 vs HFD-Saline: p < 0.001, HFD-BBR vs HFD-Saline: p < 0.01, HFD-B125 vs HFD-BBR: p < 0.01; during the dark cycle, the carbon dioxide consumption of the three groups of mice was 619.86ml / kg / h, 768.65ml / kg / h and 855.04ml / kg / h, respectively. The statistical results showed that HFD-B125 vs HFD-Saline: p < 0.001, HFD-BBR vs HFD-Saline: p < 0.05, HFD-B125 vs HFD-BBR: p < 0.05. Therefore, whether it is a light cycle or a dark cycle, the effect of B125 is significantly better than that of BBR. Therefore, the present invention believes that the berberine derivative NBD-125 can significantly enhance the metabolism and heat production of obese mice induced by a high-fat diet, thereby inhibiting weight gain, and its effect is significantly better than that of berberine.

[0046] 3. Effect of B125 on adipogenesis in C57BL / 6 obese mice induced by high-fat diet

[0047] After the metabolic cage experiment, the mice were killed, and the subcutaneous white adipose tissue, visceral white fat, and brown adipose tissue (BAT) of each mouse in the three HFD groups (HFD-Saline, HFD-BBR, and HFD-B125) were dissected and collected, weighed, and the values ​​were recorded. Then, various fats / total body weight were used to calculate the average values ​​of total white adipose tissue, subcutaneous white fat, visceral white fat, and brown fat content of mice in each group (n=5) and plotted. The experimental results are shown in Figure 2. Figure 1 b in Figure 1 In c, Figure 1 In d, Figure 1 As shown in Figure e, BBR and B125 can reduce the white fat content in mice from 13.63% to 8.69% and 6.88%, respectively, reduce subcutaneous white fat from 6.58% to 3.91% and 3.27%, respectively, and reduce visceral white fat from 6.78% to 4.78% and 3.61%, respectively. Both can significantly inhibit the reduction of white fat in C57BL / 6 obese mice induced by a high-fat diet, while the weight of brown fat remains unchanged; and B125 has a more significant inhibitory effect on visceral white fat than BBR (p < 0.05).

[0048] At the same time, the collected white adipose tissue (WAT) and brown adipose tissue (BAT) were stained with HE, and the number and proportion of white and brown fat cells of different sizes were counted using software. The results showed that the area of ​​white adipose tissue of mice injected intraperitoneally with 10μM / kg B125 (HFD-B125, intraperitoneal injection once every 2 days for 60 days) was 2000-5000μm 2 The number of cells in the 500-1000 μm 2 The number of cells increased significantly (from 13.25% to 32.53%, p < 0.05) ( Figure 1 f in Figure 1 g), indicating that B125 can significantly inhibit the enlargement of white adipocytes and exert the effect of inhibiting the formation of white adipocytes. The effect of B125 is significantly different from that of BBR (p < 0.05). Figure 1 f in Figure 1 As shown in h, the area of ​​brown adipose tissue in mice injected intraperitoneally with 10 μM / kg B125 (HFD-B125, intraperitoneal injection once every 2 days for 60 days) was 200-500 μm 2 The number of cells in the 10-50 μm 2 The number of cells in the brown adipose tissue increased significantly (from 39.38% to 50.65%, p < 0.001); the area of ​​brown adipose tissue in the mice injected intraperitoneally with 10 μM / kg BBR (HFD-B125, intraperitoneal injection once every 2 days for 60 days) was 200-500 μm 2 The number of cells in the 10-50 μm 2 The number of cells increased significantly (from 39.38% to 47.45%, p < 0.01); combined with Figure 1 A comprehensive analysis of the results of e in shows that brown fat cells have enhanced function and greater potential.

[0049] 2. In vitro cell model: Effect of B125 on preadipocyte differentiation

[0050] 1. Cultivation and differentiation induction of preadipocytes 3T3-L1 (Shanghai Cell Bank, Chinese Academy of Sciences (Catalog No.: GNM25))

[0051] (1) At 5% CO 2Under the conditions of concentration, 37°C, and 95% humidity, 3T3-L1 preadipocytes were cultured in normal culture medium with an inoculation density of about 50-60%. When the cell density reached about 90%, they were passaged (about 2-3 days) to prevent overcrowding of cells from affecting differentiation potential;

[0052] (2) Inoculate cells at 70% of the plating density into a culture dish and culture them in normal culture medium for 2 days, changing the medium approximately every 2 days until the cells are fully grown; then continue culturing for 2 days to allow the cells to fully undergo contact inhibition;

[0053] (3) Change to induction medium, this time is counted as day 0, and the induction differentiation lasts for 2 days;

[0054] (4) Continue to culture with mature medium for 4 days, changing the medium every 2 days;

[0055] (5) Change to normal culture medium and continue culturing for 2 days. At this point, it has been 8 days since the start of differentiation induction. Large lipid droplets can be seen under an optical microscope. The cells can be cultured for 10 or 12 days to fully differentiate and mature.

[0056] *Normal culture medium: 90% low-glucose DMEM + 10% calf serum NCS;

[0057] *Induction medium: 90% high glucose DMEM + 10% fetal bovine serum FBS + 850nM Insulin + 0.5mM IMBX + 1μM Dexamethasone + 1nM T3;

[0058] *Maturation medium: 90% high glucose DMEM + 10% fetal bovine serum FBS + 850nM Insulin + 1nM T3.

[0059] * Cells before induction are represented by Un, which stands for uninduced, and the time point of induction culture medium is 0d or 0h.

[0060] 2. Flow cytometry to detect the effect of B125 on early mitotic clones of 3T3-L1 preadipocytes

[0061] At 0h (un) of inducing differentiation of pre-adipocytes 3T3-L1, 0μM (Vehicle, i.e. DMSO), 5μM, and 10μM B125 were added for incubation, and the cells were collected at 16h and 28h, respectively. Accordingly, 5μM and 10μM BBR were set as positive controls. The cells were fixed with pre-cooled 70% ethanol overnight; centrifuged at 1500rpm, 4℃ for 5min, and the supernatant was discarded; the cells were resuspended with PBS; 10mg / mL of RNase A was added for incubation for 30min, centrifuged at 1500rpm, 4℃ for 5min, the supernatant was discarded, and the cells were resuspended with 300μl PBS and placed on ice; 2μl PI (2mg / mL) was added for staining for 5min before loading. The cell cycle was determined by flow cytometry and analyzed using Flow J software. The results are shown in the figure. Figure 3 As shown, after treatment with different concentrations of B125 for 16 h, the cell cycle distribution of the early mitotic clone stage of adipocyte differentiation changed (specific data are shown in Table 1). Figure 3 It can be seen that after 16 hours of treatment with BBR and B125, both can cause an increase in G0 / G1 phase cells and slow down mitotic clones, and the effect of B125 is significantly better than that of BBR; after 28 hours of treatment with BBR and B125, both can cause an increase in G2 / M phase cells and slow down mitotic clones, and the effect of B125 is significantly better than that of BBR. Therefore, B125 can significantly block the mitotic clones in the early stage of 3T3-L1 differentiation, thereby inhibiting the entire process of fat differentiation, and the effect is significantly better than that of BBR (results are shown in Figure 3 Table 1 Distribution of cell cycle in the early mitotic clonal stage of preadipocyte differentiation after B125 treatment for 16h and 28h

[0062]

[0063]

[0064] 3. Effect of B125 on lipid accumulation in the middle and late stages of differentiation of preadipocytes 3T3-L1

[0065] 3.1 Oil red staining and light microscopy observation

[0066] (1) Prepare Oil Red stock solution: weigh 150 mg of Oil Red O powder, add 50 ml of 99% isopropanol solution, shake well, and set aside;

[0067] (2) Prepare Oil Red working solution: dilute the Oil Red stock solution with double distilled water in a ratio of 3:2, mix well, filter with filter paper, and set aside;

[0068] (3) Fixing cells: Take out the cells from the incubator, remove the culture medium of differentiated mature adipocytes, wash once with PBS, and fix with 0.5% glutaraldehyde at room temperature for 1 h;

[0069] (4) Washing: remove glutaraldehyde, wash again with PBS and dry, add 60% isopropanol, and let stand for 5 min at room temperature;

[0070] (5) Staining: Discard the isopropanol solution, then take an appropriate amount of the previously filtered oil red working solution and add it to the sample well. Place the culture dish on a shaker and gently shake the culture dish for 10 minutes to evenly distribute the oil red throughout the culture dish to ensure that the lipid droplets are colored.

[0071] (6) Take photos: Discard the oil red dye in the culture dish and use ddHO 2 O was washed several times, and finally PBS was added. The lipid droplets were directly photographed under a phase contrast microscope. The results are shown in the attached Figure 4 a in.

[0072] 3.2 Determination of triglyceride (TG) content

[0073] At 0h of differentiation induction of pre-adipocytes 3T3-L1 (labeled as Un before differentiation induction), 0μM, 5μM, and 10μM B125 were added and incubated for 48h; differentiation induction was continued until the 8th day, and cells in the control group, B125 group, and positive BBR group were collected. Lysis was performed on ice with RIPA lysis buffer for 15min, ultrasonicated for 5 seconds / time, three times, and centrifuged at 12000rpm4℃ for 20min, and the supernatant was collected; the supernatant protein concentration was determined, and the TG content was determined using an automatic biochemical analyzer according to the instructions. The measurement results are shown in Figure 4 As shown in b, 5μM and 10μM BBR significantly inhibited the lipid accumulation of 3T3-L1 pre-adipocyte differentiation (the inhibition rates were 45.38% and 68.48%, p<0.001 and p<0.001, respectively); 5μM and 10μM B125 significantly inhibited the lipid accumulation of 3T3-L1 pre-adipocyte differentiation (the inhibition rates were 66.92% and 71.55%, p<0.001 and p<0.001, respectively). At a concentration of 5μM, the inhibitory effect of B125 was significantly better than that of BBR (p<0.05)

[0074] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creative work, and these embodiments all fall within the scope of protection of the present invention.

Claims

1. Use of berberine derivative NBD-125 in the preparation of drugs for preventing and / or treating obesity.

2. The use according to claim 1, characterized in that: The obesity includes obesity induced by a high-fat diet.

3. Application of berberine derivative NBD-125 in the preparation of drugs for inhibiting weight gain.

4. Use of berberine derivative NBD-125 in the preparation of drugs for enhancing metabolism and / or heat production.

5. Application of berberine derivative NBD-125 in the preparation of drugs for inhibiting white fat production.

6. The use according to claim 5, characterized in that: The inhibition of white fat production includes inhibiting the increase of white fat and / or inhibiting the enlargement of white fat cells.

7. Application of berberine derivative NBD-125 in the preparation of drugs for enhancing the function of brown adipocytes.

8. Use of a berberine derivative NBD-125 in the preparation of a drug for inhibiting the differentiation of preadipocytes into adipocytes and / or lipid accumulation.

9. The use according to claim 8, characterized in that: The inhibiting of differentiation of preadipocytes into adipocytes includes inhibiting early mitotic clones of preadipocyte differentiation.

10. The use according to any one of claims 1 to 9, characterized in that: The structure of the berberine derivative NBD-125 is shown in Formula I: